Glucagon-Like Peptide-1 (GLP-1) Metabolism in the Setting of Acute Neprilysin Inhibition
Brief Description Of Study
The purpose of this study is to determine if the medicine sacubitril/ valsartan will raise levels of the hormone glucagon-like peptide-1 (GLP-1) after a meal that may be beneficial for controlling blood sugar. We are also measuring if this pill will lower triglycerides. A large percent of people with high blood pressure also have pre-diabetes or diabetes and risk of heart disease so learning more about its effects related to blood sugar and cholesterol lowering is important.
All of the medications used in the study have been approved by the Food and Drug Administration (FDA). Valsartan is used for the treatment of high blood pressure. Sacubitril/ valsartan is approved for use in patients with heart failure with reduced ejection fraction (decreased ability of the heart to pump blood out effectively). It has also been studied in people with high blood pressure without heart failure, although it is not FDA approved for this indication at this time. The use of sacubitril/valsartan in this study is investigational.
Clinical Study Identifier: NCT03508739
Detailed Study Description
To test if sacubitril/valsartan raises GLP-1 levels (and improves insulin and glucose after a meal) compared to valsartan, you will receive one of each of these medications on study day 2 and 3 in random order. The study days will be identical with the exception of which medication you receive.
You will be asked to participate in the study for approximately 5 weeks. It may be for a shorter period if you do not need to washout from any of your current medications. If you choose to participate, you will be compensated a total of $225 for completing the 3 study days.
ClinicalTrials.gov Identifier: NCT03508739